Reports Q4 adjusted EBITDA $20.3M vs. $10.2M last year. “I am encouraged by the progress made in 2023, the first year of our two-year plan to fortify the foundation of the business,” said Ken Burdick, Chairman and CEO of LifeStance. “We remain focused on operational improvements, profitable growth, and disciplined capital deployment. Our 2024 guidance reflects the strong positive momentum of the organization. We look forward to continuing to invest in the patient and clinician experience while at the same time delivering margin expansion and positive free cash flow.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LFST:
- LifeStance Health Group Shares Informative Investor Presentation
- LifeStance Reports Fourth Quarter and Full Year 2023 Results
- LifeStance to Host Fourth Quarter and Full Year 2023 Earnings Conference Call on February 28, 2024
- LifeStance Health Resolves Litigation with Financial Settlement
- LifeStance tells Bloomberg short-seller report ‘designed to mislead investors’
